BMO Raises Novo Nordisk A/S (NVO) Price Target but Flags Prescription Pressures

Group 1 - Novo Nordisk A/S is considered one of the most profitable healthcare stocks, with BMO Capital raising its price target from $47 to $57 while maintaining a Market Perform rating [1] - BMO Capital has reduced its 2025 sales estimate for Wegovy to DKK 77.8 billion from DKK 79.8 billion, slightly below the consensus forecast of DKK 78.4 billion, citing ongoing pricing pressures [2] - The company experienced flat prescription trends for Wegovy in Q4 2025 compared to Q3 2025, with expectations of a similar flat U.S. prescription volume in 2026 leading to negative year-over-year net sales growth [2] Group 2 - Wegovy was prescribed over 18,000 times in the U.S. during its first full week post-launch, indicating strong early demand in a well-established obesity market [3] - Novo Nordisk operates in two segments: Diabetes and Obesity Care, and Rare Disease, highlighting its focus on specialized pharmaceutical products [3]